Search company, investor...
COTA company logo

COTA

cotahealthcare.com

Founded Year

2011

Stage

Series D - II | Alive

Total Raised

$115.7M

Revenue

$0000 

About COTA

COTA provides healthcare services for cancer-affected patients. It combines its proprietary technology and analytics solutions to inform decisions and actions. COTA partners with life sciences companies to reveal insights to accelerate drug development and helps uncover previously unknown insights. The company was founded in 2011 and is based in Boston, Massachusetts.

Headquarters Location

609 Greenwich Street 4th Floor

New York, New York, 10014,

United States

866-648-3833

COTA's Product Videos

ESPs containing COTA

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Care Delivery & Navigation Tech

The oncology clinical decision support (CDS) market is focused on using technology to support healthcare providers in making more informed and personalized treatment decisions for cancer patients. These solutions leverage data analytics, artificial intelligence, and other advanced technologies to provide clinicians with real-time access to patient data, treatment guidelines, and clinical research.

COTA named as Highflier among 13 other companies, including Tempus, Datavant, and Syapse.

Compete with COTA?

Ensure that your company and products are accurately represented on our platform.

COTA's Products & Differentiators

    Focus

    In traditional randomized controlled trials (RCTs), a group of patients is randomized into experimental and control arms, the latter of which typically account for 33–50% of study participants. While patients in the control arm are put through the same demanding requirements as the experimental arm — hospital visits, blood draws, and other invasive diagnostics to monitor the cancer — they neither receive the new therapy nor are made aware of this fact. In other words, if you were a clinical trial participant, you do not know if you are going through all this to receive a promising new treatment or just the standard of care (or worse, a placebo, i.e., “sugar pill”). When sponsors use Focus, all patients will receive the drug being studied. The control group is composed of COTA's data curated from electronic health records.

Research containing COTA

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned COTA in 1 CB Insights research brief, most recently on Dec 21, 2022.

Expert Collections containing COTA

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

COTA is included in 6 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Digital Health

10,347 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

H

Healthcare interoperability

174 items

H

Health IT

87 items

COTA Patents

COTA has filed 13 patents.

The 3 most popular patent topics include:

  • Data management
  • Electronic health records
  • Health informatics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/12/2018

1/26/2021

Psychiatric diagnosis, Health informatics, Healthcare quality, Medical terminology, Smoking

Grant

Application Date

2/12/2018

Grant Date

1/26/2021

Title

Related Topics

Psychiatric diagnosis, Health informatics, Healthcare quality, Medical terminology, Smoking

Status

Grant

Latest COTA News

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2023 Annual Meeting

May 28, 2023

Fintech News May 28, 2023 NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced that the company and its collaborators will present a total of 12 abstracts accepted for poster discussion, presentation, and online publication at this year’s American Society of Clinical Oncology (ASCO) Annual meeting, to be held in Chicago this June. “As demonstrated by our presence at ASCO this year, Flatiron is continuing to scale our ability to connect powerful data and novel technology to better design trials for diversity, accelerate clinical research timelines, reduce burden across teams and complete trials with more confidence,” shares Flatiron Health Chief Medical Officer Javier Jimenez. “Aligned with this year’s theme, Flatiron’s intimate knowledge of the oncology healthcare ecosystem and multi-faceted and deep understanding of EHR data positions us to continue developing technology and driving research to close the gap between care and research.” Research highlights include: A Poster Discussion Session highlighting the mediators of racial and ethnic inequities in clinical trial participation among US patients with cancer. An Oral Abstract Session discussing a collaboration between Flatiron Health and Foundation Medicine to measure tumor mutational burden (TMB) from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. An Oral Abstract Session discussing research done by the Health Equity One-Roche Collaboration (Flatiron Health, West Clinic, OneOncology, Foundation Medicine, and Genentech) to understand practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients with advanced non-small cell lung cancer (aNSCLC) treated in the community setting. This study was invited to submit a manuscript for simultaneous publication in the Journal of Clinical Oncology – Oncology Practice. Learn more about our abstracts and events by visiting our website . Follow Flatiron Health on Twitter and LinkedIn for more updates from #ASCO23 and visit us in person at Booth #23127. Poster Discussions and Presentations Jenny S. Guadamuz, Xiaoliang Wang, Ivy Altomare, Gregory S. Calip Partner: Foundation Medicine David R. Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel Klempner, Miles Andrews, Amit Mahipal, Vivek Subbiah, Ramez Eskander, David Carbone, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Gerald Li, Julia C. F. Quintanilha, Richard S.P. Huang, Jeffrey S. Ross, David Fabrizio, Geoffrey R. Oxnard, Ryon P. Graf Partner: Health Equity One-Roche Collaboration — Flatiron Health, West Clinic, OneOncology, Foundation Medicine, and Genentech Gregory Vidal, Neha Jain, Aaron Fisher, Danny Sheinson, Katherine T. Lofgren, Esprit Ma, Elaine Yu, Leah Comment, Rebecca Miksad, Davey Daniel Maneet Kaur, Filip Frahm, Mustafa Ascha, Jenny Guadamuz, Adam Gottesman, Barry Leybovich, Arjun Sondhi, Yihua Zhao, Neal J. Meropol, Trevor Royce Partner: Friends of Cancer Research (FoCR) — FDA, Flatiron Health, Syapse, Cota, ConcertAI, McKesson, Tempus Xinran Ma, Friends of Cancer Research, ASCO, FDA, ConcertAI, COTA, Guardian Research Network, IQVIA, Ontada, Syapse, and Tempus Partner: Foundation Medicine Debra Richardson, Julia Quintanilha, Ryon Graf, Natalie Danziger, Christina Washington, Lauren Dockery, Tamara Snow, Anosheh Afghahi, Anthony Frachioni, Julia Elvin, Kathleen Moore Partner: Yale University Maureen Canavan*, Xiaoliang Wang*, Mustafa Ascha, Rebecca Miksad, Timothy N. Showalter, Gregory Calip , Cary P. Gross, Kerin Adelson *These authors contributed equally to the work. Ravi Parikh, Xavier Orcutt, Arjun Sondhi, Aaron Cohen Partner: University of Pennsylvania Christopher D’Avella, Erin Bange, Aditi Singh, David Dougherty, Peter Gabriel, Rebecca Maniago, Jennifer Miao, Colin Harvey, Marcello Ricottone, Lawrence N. Shulman About Flatiron Health Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth Contacts We provide you with the latest breaking news and videos straight from the business. The website www.fintechnews.org (referred to as "the Website") serves as a platform for sharing information and articles related to the fintech industry. The content published on the Website may include articles, opinions, or other forms of third-party contributions. Please note that the views and opinions expressed in these articles are solely those of the respective authors and do not necessarily reflect the views of www.fintechnews.org or its affiliates. We do not endorse, support, or guarantee the accuracy, completeness, or reliability of any information or content provided by third-party contributors. www.fintechnews.org shall not be held responsible for any loss, damage, or inconvenience arising from the use of or reliance on the information and content published on the Website. Users are advised to exercise their own judgment and discretion when interpreting and relying on the information provided. Furthermore, www.fintechnews.org does not have any control over the content, quality, or legality of external websites or resources that may be linked to or referenced on the Website. Any access or reliance on such external websites or resources is done at the user's own risk, and www.fintechnews.org shall not be liable for any consequences or damages incurred. We make every effort to ensure the accuracy and reliability of the content published on the Website. However, we cannot guarantee the timeliness, completeness, or suitability of the information provided. Users are encouraged to verify any information before making decisions based on it. The inclusion of any advertisements, sponsored content, or links to third-party websites on www.fintechnews.org does not imply endorsement or recommendation by www.fintechnews.org . We are not responsible for the content, products, or services provided by these third-party entities. By using the Website, you acknowledge and agree to the above disclaimer. If you do not agree with any part of this disclaimer, please refrain from accessing or using the Website. This disclaimer is subject to change without prior notice. It is recommended to review this disclaimer periodically for any updates. If you have any questions or concerns regarding this disclaimer, please contact us at info@fintechnews.org

COTA Frequently Asked Questions (FAQ)

  • When was COTA founded?

    COTA was founded in 2011.

  • Where is COTA's headquarters?

    COTA's headquarters is located at 609 Greenwich Street, New York.

  • What is COTA's latest funding round?

    COTA's latest funding round is Series D - II.

  • How much did COTA raise?

    COTA raised a total of $115.7M.

  • Who are the investors of COTA?

    Investors of COTA include Deerfield Management, dRx Capital, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Baptist Health South Florida and 15 more.

  • Who are COTA's competitors?

    Competitors of COTA include Mendel AI and 3 more.

  • What products does COTA offer?

    COTA's products include Focus and 3 more.

Compare COTA to Competitors

ConcertAI Logo
ConcertAI

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

Syapse Logo
Syapse

Syapse develops software for aggregating and structuring biomedical data. It combines data intelligence, insight analytics and applied experience through healthcare organizations looking to transform patients’ lives using real-world evidence. The company was founded in 2008 and is based in San Francisco, California.

xCures Logo
xCures

xCures is a health technology company that has created an AI- and expert-supported Perpetual Clinical Trial platform that continuously learns from all patients, on all treatments, all the time. It provides patients, and their physicians, with individualized treatment options and facilitates access via reimbursement, clinical trials and expanded-access support.

M
Mango Sciences

Mango Sciences operates as an emerging market data science company. It improves patient access and powers global health innovation. The company offers a platform that utilizes artificial intelligence (AI) analytics to transform deep clinical data into key insights. It was founded in 2012 and is based in Boston, Massachusetts.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility. The company enables physicians to deliver personalized cancer care for patients through analytical and machine-learning platforms. It provides genomic sequencing services and molecular therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. It was formerly known as Tempus Consulting. The company was founded in 2015 and is based in Chicago, Illinois.

Evidation Logo
Evidation

Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.